Authors: J. Hradec Authors‘ workplace: III. interní klinika 1. lékařské fakulty UK a VFN, Praha Published in: Kardiol Rev Int Med 2010, 12(1): 33-37
The aim of the BEAUTIFUL clinical trail was to evaluate whether lowering of the heart rate (HR) with the specific sinoatrial node If channels inhibitor ivabradine in patients with stabilized ischemic heart disease (IHD) and left ventricular systolic dysfunction leads to a reduction in cardiovascular mortality and morbidity. The study placebo arm served for testing the hypothesis that elevated resting HR is a marker of subsequent cardiovascular mortality and morbidity. The study involved 10 970 patients with documented IHD and left ventricular ejection fraction of
Key words: angina pectoris – ivabradine – BEAUTIFUL clinical trial – heart rate reduction – cardiovascular mortality – cardiovascular morbidity
1. Fox K, Ferrari R, Tendera M et al. BEAUTIFUL Steering Comitee. Rationale and design of a randomized, double‑blind, placebo ‑ controlled trial of ivabradine in patients with stable coronary artery disease and left ventricular systolic dysfunction: the morBidity ‑ mortality EvAlUaTion of the If inhibitor ivabradine in patiens with coronary disease and left ventricULar dysfunction (BEAUTIFUL) study. Am Heart J 2006; 152 : 860 – 866.
2. DiFrancesco D, Camm AJ. Heart rate lowering by a specific and selective If current inhibition with ivabradine: A new therapeutic perspective in cardiovascular disease. Drugs 2004; 64 : 1757 – 1765.
3. Kannel WB, Kannel C, Paffenberger RS jr et al. Heart rate and cardiovascular mortality: the Framingham study. Am Heart J 1987; 113 : 1489 – 1494.
4. Palatini P, Casiglia E, Paulleto P. Relation between physical training and ambulatory blood pressure in stage I hypertensive subjects: results of the HARVEST trial. Circulation 1994; 90 : 2870 – 2872.
5. Diaz A, Bourassa MG, Guertin MC et al. Long‑term prognostic value of resting heart rate in patients with suspected or proven coronary artery disease. Eur Heart J 2005; 26 : 967 – 974.
6. Hjalmarson A, Gilpin EA, Kjekshus J et al. Influence of heart rate on mortality after acute myocardial infarction. Am J Cardiol 1990; 65 : 547 – 553.
7. Kjekhus J, Gullestad L. Heart rate as a therapeutic target in heart failure. Eur Heart J 1999; (suppl H): H64 – H69.
8. Hradec J. Selektivní ovlivnění srdeční frekvence – nový fenomén v kardiovaskulární farmakoterapii. Remedia 2008; 18 : 114 – 119.
9. Reil JC, Böhm M. The role of heart rate in the development of cardiovascular disease. Clin Res Cardiol 2007; 96 : 585 – 592.
10. Kjekshus JK. Importance of heart rate in determining beta‑blocker efficacy in acute and long‑term acute myocardial infarction intervention trials. Am J Cardiol 1986; 57 : 43F – 49F.
11. Cucherat M. Quantitative relationship between resting heart rate reduction and magnitude of clinical benefits in post‑myocardial infarction. A meta‑regression of randomized clinical trials. Eur Heart J 2007; 28 : 3012 – 3019.
12. Fox K, Ford I, Steg PG et al. BEAUTIFUL Investigators. Ivabradin for patients with stable coronary artery disease and left ‑ ventricular systolic dysfunction (BEAUTIFUL): a randomised, double‑blind, placebo ‑ controlled trial. Lancet 2008; 372 : 807 – 816.
13. Fox K, Ford I, Steg PG et al. BEAUTIFUL Investigators. Heart rate as a prognostic risk factor in patients with coronary artery disease and left ‑ ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomised cotrolled trial. Lancet 2008; 372 : 817 – 821.
14. Fox K, Ford I, Steg G et al. BEAUTIFUL Investigators. Relationship between ivabradine treatment and cardiovascular outcomes in patients with stable coronary artery disease and left ventricular systolic dysfunction with limiting angina: a subgroup analysis of the randomized, controlled BEAUTIFUL trial. Eur Heart J 2009; 30 : 2337 – 2345.
15. Fonarow GC, Abraham WT, Albert NM et al. Dosing of beta‑blocker therapy before, during, and after hospitalization for heart failure (from Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients With Heart Failure). Am J Cardiol 2008; 102 : 1524 – 1529.
16. Gislason GH, Rasmussen JN, Abildstrom SZ et al. Long‑term compliance with beta‑blocker, angiotensin‑converting enzyme inhibitors, and statins after acute myocardial infarction. Eur Heart J 2006; 27 : 1153 – 1158.
17. Wiest FC, Bryson CL, McDonnel MB et al. Suboptimal pharmacotherapeutic management of chronic stable angina in the primary care setting. Am J Med 2004; 117.
Don‘t have an account? Create new account
Enter the email address that you registered with. We will send you instructions on how to set a new password.
